BRIEF-Morgan Stanley's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Decreases To 2.76% On Dec 8 - HKEX

Jiangsu Hengrui Medicine Co. Ltd. Announces Date for 2025 Second Extraordinary Shareholders' Meeting

Hengrui Pharma Facilitates Chinese Medical Excellence at Italian Digestive Surgery Conference for Second Consecutive Year

HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List

Jiangsu Hengrui Medicine Drugs Added to China’s National Reimbursement Drug List

Jiangsu Hengrui Medicine Appoints Zhu Guoxin as Senior Vice President at Board Meeting

FTSE China 50 Index Rebalance: Adds CHINAHONGQIAO (01378), CATL (03750), HENGRUI PHARMA (01276), Removes CSC (06066) and Others

GIC Private Limited Increases Stake in Hengrui Pharma (01276) by 422,400 Shares at HK$74.96 per Share

Morgan Stanley Increases Stake in Hengrui Pharma by 1.77 Million Shares at Average Price of HK$69.65

Wellington Management Group LLP Increases Stake in Hengrui Pharma (01276) by 1 Million Shares at HK$69.15 per Share

HENGRUI PHARMA (600276.SH): HRS-8364 Tablets Approved for Clinical Trials

HENGRUI PHARMA (600276.SH): Marketing Authorization Application for Aumolertinib Sulfate Tablets Accepted

Hong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Over 5% as 9 Drugs Including SHR-9839 Injection Approved for Clinical Trials

HENGRUI PHARMA (01276) Repurchases 250,000 Shares for Approximately HK$14.88 Million on November 21

Morgan Stanley's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Increases to 6.48% on Nov 18 From 5.94% - HKEX

HENGRUI PHARMA (01276) Repurchases 209,900 A Shares for RMB12.74 Million on November 20

Hong Kong Stock Movement | HENGRUI PHARMA (01276) Rises Nearly 3% as Fumarate Tegileridine Injection Receives Clinical Trial Approval